

Typically resilient 3M stock has pulled back some more since our J uly review. It is down roughly $17 \%$ from its high price set back in March after declining some $5 \%$-plus over the past three months. Although broader market concerns probably played a role, we believe that investors took issue with the company's second-quarter results. Indeed, J unequarter earnings came in at $\$ 2.02$ per share, pennies ahead of guidance and $6 \%$ ahead of the year-before mark, but the most recent figure is based on 21.6 million fewer shares outstanding. Earnings improved a more modest $2.6 \%$ on an apples-to-apples basis. The top line raised even more eyebrows, with sales dropping 6\%, twice as much as we were anticipating.
Guidance likely did little to alleviate investor angst. Pointing to global economic sluggishness and currency headwinds, management said that it now expects 3 M to earn $\$ 7.80$ to $\$ 8.00$ a share for the full year, down from its previous $\$ 7.80$ to $\$ 8.10$ range. It also cut its top-line outlook, now forecasting a $2.0 \%$ to $4.5 \%$ sales decline for the year.
company faces, but are leaving intact our full-year share-net estimate at $\$ 7.90$. Although we've trimmed our topline call to reflect the aforementioned concerns, 3 M is doing a good job on the cost side of the ledger and increasing margins. Plus, we expect share repurchases to remain atop management's agenda. In that vein, a 6\% share-net advance seems achievable in the second half of the year, with a double-digit gain plausible next year.
Now may be a good time to initiate a stake in timely 3M stock. The recent share-price weakness presents a good buying opportunity for risk-averse, buy-and-hold-investors seeking total return. Management continues to streamline the business model, using strong cash flow generation and the proceeds from divestitures of peripheral operations to make acquisitions and strengthen its position in core businesses. Recently, the company hired Goldman Sachs to explore strategic options regarding its Health Information Systems segment, but said that it is intent on expanding the Health Care unit. AndreJ. Costanza

October 16, 2015
A) Diluted earnings. Excludes nonrecurring: '99, 7¢; '00, (10¢); '01, (5¢); '10, (12¢). Excludes discontinued: '06, 47¢; '07, 60¢. Earn-
(B) Dividends historically paid mid-March June, September, and December. - Dividend
reinvestment plan available.
(C) In millions, adjusted for stock split.

Company's Financial Strength Stock's Price Stability
Price Growth Persistence

